Publications by authors named "C Piperidou"
Article Synopsis
- The study investigates the differences between patients with embolic strokes of undetermined source (ESUS) and those with cardioembolic stroke (CE), focusing on clinical characteristics and outcomes.
- The findings show that patients with ESUS tend to be younger, experience less severe initial symptoms, have lower rates of cerebral edema, and generally achieve better functional outcomes over time compared to those with CE.
- ESUS patients also exhibit significantly lower mortality rates after one year, suggesting distinct underlying mechanisms and the need for different management strategies for these two stroke types.
Embolic stroke of undetermined source (ESUS) represents a subgroup of cryptogenic ischemic stroke (CS) distinguished by high probability of an underlying embolic mechanism. There are scarce population-based data regarding the incidence, characteristics and outcomes of ESUS. Consecutive patients included with first-ever ischemic stroke of undetermined cause in the previously published population-based Evros Stroke Registry were further subdivided into ESUS and non-ESUS CS.
View Article and Find Full Text PDFUp to date there is no population-based study from Greece providing long-term data on incidence of both all-cause mortality and stroke recurrence for patients with first ever stroke (FES). Adult patients with FES were registered during a 24-month period (2010-2012) and followed-up for 12 months. We calculated cumulative incidences of stroke mortality and recurrence.
View Article and Find Full Text PDFBackground And Purpose: Data are scarce on both stroke incidence rates and outcomes in Greece and in rural areas in particular. We performed a prospective population-based study evaluating the incidence of first-ever stroke in the Evros prefecture, a region of a total 147 947 residents located in North Eastern Greece.
Methods: Adult patients with first-ever stroke were registered during a 24-month period (2010-2012) and followed up for 12 months.
Introduction: The aim was to examine the influence of the SCN1A gene polymorphism IVS5-91 rs3812718 G>A on the response to antiepileptic drugs (AEDs) in monotherapy or polytherapy.
Material And Methods: Two hundred epilepsy patients and 200 healthy subjects were genotyped for SCN1A IVS5-91 rs3812718 G>A polymorphism using TaqMan assay. Patients were divided into drug-responsive and drug-resistant patients.